Molecular Weight(MW): 246.3
Busulfan is a cell cycle non-specific alkylating antineoplastic agent.
Purity & Quality Control
Choose Selective DNA alkylator Inhibitors
|Description||Busulfan is a cell cycle non-specific alkylating antineoplastic agent.|
Busulfan inhibits the cobblestone area-forming cell frequency but fails to cause a significant increase in apoptosis in hematopoietic stem cell alike cells and progenitors. Busulfan inhibits the hematopoietic function of HSC alike cells and progenitors via an apoptosis-independent mechanism. Busulfan induces bone marrow hematopoietic cell senescence associated with an increased expression of p16Ink4a and p19Arf in a time-dependent manner.  Busulfan, an alkylating agent that causes DNA damage by cross-linking DNAs and DNA and proteins, induces senescence in normal human diploid WI38 fibroblasts through the extracellular signal-regulated kinase (Erk) and p38 mitogen-activated protein kinase (p38 MAPK) cascade independent of the p53-DNA damage pathway. Busulfan induces a transient reduction in GSH but a continuous increase in ROS production.  Busulfan-induced hypophosphorylation of Rb prevents apoptosis of spermatogonial stem cells by inhibiting PCNA expression in testicular cells. 
|In vivo||Busulfan-treated mice exhibit a marked increase in apoptosis and a decrease in testis weight. Busulfan is administered at the rate of 40 mg/kg body weight to induce a maximal number of apoptotic cells while minimizing the number of necrotic cells.  Busulfan conditioning and irradiation results in comparable sensitivity of HSC detection as evaluated by limiting dilution analysis in NOD/SCID mice.  Busulfan-transplanted mice has slow and incomplete lymphoid engraftment. Busulfan (20 mg/kg to 100 mg/kg) provides dose-dependent congenic lymphoid reconstitution in mice. |
-  Meng A, et al. Cancer Res, 2003, 63(17), 5414-5419.
-  Probin V, et al. Free Radic Biol Med, 2007, 42(12), 1858-1865.
-  Choi YJ, et al. FEBS Lett, 2004, 575(1-3), 41-51.
|In vitro||DMSO||49 mg/mL (198.94 mM)|
|In vivo||Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02629120||Recruiting||X-Linked Chronic Granulomatious Disease||National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)||December 3, 2015||Early Phase 1|
|NCT01176006||Recruiting||DOCK8 Deficiency||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||July 28, 2010||Phase 2|
|NCT02750254||Recruiting||Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia||Washington University School of Medicine||June 27, 2016||Phase 1|Phase 2|
|NCT02250937||Recruiting||Acute Myeloid Leukemia|Myelodysplastic Syndrome||M.D. Anderson Cancer Center||October 27, 2014||Phase 2|
|NCT01861106||Recruiting||GATA2|Immunodeficiency|MDS||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||April 26, 2013||Phase 2|
|NCT01701986||Recruiting||Lymphoma||M.D. Anderson Cancer Center||October 25, 2012||Phase 1|Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
How can I reconstitute the drug for in vivo studies?
This compound also can be dissolved in 2% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5mg/ml as a clear solution. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG and Tween. After they mixed well, dilute with water. S1692 in this formulation is not suitable for long-term storage. Please make the fresh solution each time before use.